Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer (BJCC-R01)
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for MRI Stratified Low-risk Rectal Cancer: a Multi-center, Prospective, Single-arm Phase II Trial.
Sponsor: Peking University Cancer Hospital & Institute
This observational or N/A phase trial investigates Rectum Cancer and is currently ongoing. Peking University Cancer Hospital & Institute leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Nov 2022 — Feb 2024 [monthly]
Recruiting
-
Dec 2021 — Nov 2022 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Nov 2020 [monthly]
Not Yet Recruiting
First recorded
May 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .